Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZ/su co-administered with Prevenar 13 in adults aged 50 years and older
2017-001220-22Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Zoster vaccine recombinant and pneumococcal 13-valent conjugate vaccine in herpes zoster (HZ) and pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Vaccine response rate to HZ/su. Started Dec 2017; status: completed.
02
Drugs
Zoster vaccine recombinantpneumococcal 13-valent conjugate vaccine
03
Conditions
herpes zoster (HZ)pneumococcal disease
Beyond the preview
Go deeper on 2017-001220-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001220-22.